Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Thrombocytopenia 1Lymphoma 1Intraocular Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1

Interventions

Rituximab 17Peripheral Blood Stem Cell Transplantation 15Cyclophosphamide 15fludarabine phosphate 12Whole-Body Irradiation 11Cyclosporine 10Mycophenolic Acid 9Etoposide 9Methotrexate 8Filgrastim 8Lenalidomide 7Tacrolimus 6Dexamethasone 6Busulfan 6Radiotherapy 5Melphalan 5Cytarabine 5Carboplatin 5Vorinostat 4Thiotepa 4Therapeutics 4Psychiatric Rehabilitation 4Bortezomib 4Antilymphocyte Serum 4Transplantation 3Methylprednisolone 3Irinotecan 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Dasatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intraocular Lymphoma × sodium thiosulfate × Lymphoid × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡